CD303 (BDCA-2), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD303 (BDCA-2), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD303 (BDCA-2), Human |
| Clone | REAL225 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | fluorescein (FITC) conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD303 (BDCA-2) Antibody, anti-human, FITC, REAlease®. Clone REAL225 is an antibody fragment derived from the full CD303 (BDCA-2) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | CD303 (BDCA-2) antibodies have been used, for example, to identify, characterize, and enumerate plasmacytoid dendritic cells in whole blood of healthy and HIV-infected individuals, and for analyzing the role of DC-SIGN in HIV infection and transmission. Furthermore, CD303 (BDCA-2) antibodies were used to identify and enumerate plasmacytoid dendritic cells in blood and bone marrow samples before and after hematopoietic stem cell mobilization or transplantation. CD303 (BDCA-2) antibodies were also used for immunohistochemical staining, for example to identify plasmacytoid dendritic cells in tissue sections from patients with different inflammatory skin diseases. | Clone REAL225 recognizes the CD303 (BDCA-2) antigen which is expressed on human plasmacytoid dendritic cells in blood, lymphoid (e.g. tonsils and bone marrow), and non-lymphoid tissue. Specific expression allows direct identification of plasmacytoid dendritic cells using just one marker. CD303 (BDCA-2)+ plasmacytoid dendritic cells in blood and bone marrow are CD11c-, CD123high, CD4+, Lin-, CD45RA+, CD304 (BDCA-4/Neuropilin-1)+, CD141 (BDCA-3)low, CD1c (BDCA-1)-, CD14-, and CD2-. They express neither myeloid lineage markers (CD13, CD33) nor Fc receptors (CD32, CD64, FcRI). CD303 (BDCA-2) is strongly expressed on freshly isolated plasmacytoid dendritic cells but down-regulated within 48 hours of culturing. Unlike CD304 (BDCA-4/Neuropilin-1), CD303 (BDCA-2) is not detectable on ex vivo generated monocyte-derived or hematopoietic precursor cell-derived CD1a+ dendritic cells. | The CD303 (BDCA-2) antigen is a type II transmembrane C-type lectin. Remarkably, plasmacytoid dendritic cells can take up ligands via CD303 (BDCA-2), then process and present the ligands to T cells. Unlike binding of antibodies to CD304 (BDCA-4), binding of antibodies to CD303 (BDCA-2) inhibits type I interferon production, which is induced in plasmacytoid dendritic cells by, for example, the influenza virus. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes. |
| Immunogen | n/a |
| Other Names | BDCA-2 |
| Gene, Accession # | n/a |
| Catalog # | 130-119-909 |
| Price | $345 |
| Order / More Info | CD303 (BDCA-2), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | n/a |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies